Bone mineral density in early breast cancer patients

Bratislava Medical Journal

Volumn 111, Issue 1, 2010, Pages 27-32

  Spanik, S ^a   Spanikova, B ^b  

^a Bratislava   (Slovakia)

^b St Elisabeth Cancer Institute   (Slovakia)

Author keywords

Adjuvant endocrine therapy; Bone marrow density; Early breast cancer

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BONE DENSITY; BREAST TUMOR; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; POSTMENOPAUSE;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN;

EID: 77952906678     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Adam Z et al. Kostní nádorová choroba. Praha Grada, 2005: 286 s.
2. Hrnčiar J. et al. Endokrinné a hormonálno-metabolické choroby. Banská Bystrica CentroMedian, 2000.
3. Bayer M et al. Metabolická onemocnení skeletu u dětí. Praha Grada, 2002.
4. Rizzoli R. Postmenopausal Osteoporosis. London Current Medicine Group Ltd, 2005: 94.
5. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists Group: http//oncology.thelancet.com. December 15, 2007.
6. Coates AS, Keshaviah A, Thurlimann B. Five years of letrozole compare with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
7. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ & Panel Members. Progress and promise: highlights of the internqational expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol; 2007 18: 1133-1144.
8. Marcus R, Feldman D, Nelson DA, Rosen CJ. Osteoporosis. Burlington MA Elsevier AP, 2008: 1939.
9. Katz MH. Multivariable Analysis: A practical Guide for Clinicians. Cambridge University Press, 2006.
10. Katz MH. Study Design and Statistical Analysis: A practical Guide for Clinicians. Cambridge University Press, 2006.
11. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Aone or in Combination) trial after completed 5 years adjuvant treatment for breaast cancer. Lancet 2005; 305: 60-62.
12. Thurliman B, Keshavian A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 2005; 353: 2747-2757.
13. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Inergroup Exmestane Study): a randomized controled trial. Lancet 2007; 369: 559-570.
14. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet; 2005 366: 455-462.
15. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl CAncer Inst 2005; 97: 1262-1271.
16. Kanis JA, Johnell O, Oden A et al. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporosis Int 2001; 12: 989-995.
17. National Osteoporosis Foundation. Physician's Guide: Pharmacologic Options. http:/www.nof.org/physguide/pharmacologic.htm.
18. World Health Organization. Technical Report Series; 921: Prevention and Management of Osteoporosis. Geneva, Switzerland WHO 2003: 1-192.
19. Siris ES, Chen YT, Abbott TA et al. Bone mineral density thresholds for pharmacogenic intervention to prevent fractures. Arch Intern Med 2004;.
20. Gnant AF, Mineritsch B, Luschin-Ebengrueth G et al. Zoledronic acid effectively prevents cancer treatment-induced bone loss in women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820-828.